Autolus Therapeutics plc
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Biotechnology
業務概覽 Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3,AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
公司地址 191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
電話號碼 +44 2038296230
傳真號碼 --
公司網頁 https://www.autolus.com
員工數量 752
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Christian Itin, PhD. Chief Executive Officer and Director -- 27/03/2026
Mr. Alex Driggs Senior Vice President, Legal Affairs and General Counsel -- 27/03/2026
Mr. Christopher Andrew Vann Senior Vice President and Chief Operating Officer -- 27/03/2026
Mr. Robert F. Dolski Senior Vice President and Chief Financial Officer -- 27/03/2026
Ms. Cintia Piccina Senior Vice President, US Chief Commercial Officer and Country General Manager -- 27/03/2026
Mr. Patrick Paul McIlvenny Senior Vice President, Finance and Chief Accounting Officer -- 27/03/2026
Mr. Alexander Swan Senior Vice President and Chief Human Resources Officer -- 27/03/2026
Dr. Christopher Michael James Williams, PhD Senior Vice President and Chief Business Development Officer -- 27/03/2026
Mr. Martin Anton Pule, M.B.B.S. Senior Vice President and Chief Scientific Officer -- 27/03/2026
Ms. Miranda Suzette Neville Senior Vice President and Chief Technology Officer -- 27/03/2026
Dr. Matthias Will, M.D. Senior Vice President and Chief Development Officer -- 27/03/2026
 
董事會成員
董事會 職務 更新日期
Dr. Christian Itin, PhD. Chief Executive Officer and Director 27/03/2026
Ms. Cynthia M. Butitta Independent Director 27/03/2026
Mr. John E. Berriman Independent Director 27/03/2026
Mr. Michael W. Bonney Chairman of the Board 27/03/2026
Mr. William D. Young, PhD Independent Director 29/06/2026
Ms. Linda C. Bain Independent Director 27/03/2026
Mr. Robert W. Azelby Independent Director 27/03/2026
Dr. Robert Iannone, M.D. Independent Director 27/03/2026
Mr. Ryan Richardson Director 27/03/2026
Dr. Elisabeth Leiderman, M.D. Independent Director 27/03/2026
Dr. Ravi Madduri Rao, PhD Independent Director 27/03/2026
 
所屬ETF (更新日期: 01/08/2026 02:06)
代號 名稱 佔比% ▼ 持有日期
IBBiShares Biotechnology ETF0.54%30/06/2026
GWXState Street® SPDR® S&P® Intl Sm Cp ETF0.03%30/06/2026
QQQSInvesco NASDAQ Future Gen 200 ETF0.02%30/06/2026
APIEActivePassive International Equity ETF0.01%30/06/2026
IBBQInvesco Nasdaq Biotechnology ETF0.004%30/06/2026
BIBProShares Ultra Nasdaq Biotechnology0.002%30/06/2026
BBCVirtus LifeSci Biotech Clinical Trls ETF<0.000001%16/12/2025
BMEBlackRock Health Sciences<0.000001%31/03/2026
BMEDiShares Health Innovation Active ETF<0.000001%26/02/2026
BMEZBlackRock Health Sciences Term Trust<0.000001%31/03/2026
CANCTema Oncology ETF<0.000001%30/10/2025
SBIOALPS Medical Breakthroughs ETF<0.000001%19/12/2025
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.